<div><p><b>Background: </b>Acute kidney injury (AKI) frequently complicates the course of hospitalized patients with cirrhosis and negatively impacts prognosis. Response to medical management in AKI is variable, depending on the etiology and severity of the injury. How AKI improvement or response affects liver transplant timing is less clear. We sought to assess the impact of AKI response to treatment on survival and liver transplantation (LT) for patients with cirrhosis waitlisted for LT.</p>

<div><p><b>Background:<strong> </b><span> </span></strong>Hepatic steatosis (HS) and a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of ≥7.5% are associated with increased risk for future cardiovascular events. However, cardiovascular risk of patients with HS at ASCVD&lt;7.5% is not clearly understood.</p>

<div><p><b>Background:</p> </b><p>We previously showed that loss of Yes-associated protein 1 (YAP) in early liver development (YAP^KO) leads to an Alagille syndrome-like phenotype, with failure of intrahepatic bile duct development, severe cholestasis, and chronic hepatocyte adaptations to reduce liver injury. TAZ, a paralog of YAP, was significantly upregulated in YAP^KO hepatocytes and interacted with TEAD transcription factors, suggesting possible compensatory activity.</p>

<div><p><b>Background:<span> </b>Progressive familial intrahepatic cholestasis (PFIC) are a group of recessive disorders linked by the inability to appropriately excrete bile salts (BS) from hepatocytes. PFIC1 results from mutations in <em>ATP8B1 </em>encoding FIC1, an apical membrane aminophospholipid translocase.

<div><p><b>Background:</p> </b><div><p><span lang="EN-US">In the context of alcohol-related liver disease (ArLD), changes in the homeostasis of the gut-liver axis have become a focus of major </span></p></div>

<div><p><b>Background:</p> </b><p>Acute variceal bleeding (AVB) is a cause of serious morbidity and mortality in cirrhosis. While more severe disease (e.g. higher Child-Turcotte-Pugh [CTP] score) has been shown to correlate with worse outcomes after AVB, it is unclear if this correlation remains universal across all cirrhosis etiologies.

<div><p><strong>Background</strong>: Minimal hepatic encephalopathy (MHE) is associated with poor outcomes but treatment strategies are limited. Rifamycin SV MMX (RiVM) is a novel rifampin derivative which a non-absorbable antibiotic with maximal impact in the colon. <u>Aim</u>: Evaluate impact of RiVM on microbiome, safety &amp; gut-brain axis in an RCT.</p>

<div><p><strong>Background</strong>: Regional differences in environment, health-care system, microbiology lab capabilities, countermeasures of drug resistance may greatly impact the occurrence and evolution of infection in cirrhosis. We aimed to assess the prevalence, characteristics, clinical impact, and variations in infection on admission (AdI) across a global population of cirrhosis inpatients.</p>

<div><p><b>Background:</p> </b><p>Early detection of liver disease has been identified as a public health priority in the UK. Symptoms are rare before advanced stages and case finding using risk factors improves identification. In financially constrained health systems, case finding in areas with greater disease burden is prudent. Socio-economic deprivation is associated with advanced liver disease. We assessed the incidence of liver disease by population deprivation using a community case finding pathway.</p>

<div><p><b>Background: </b>Liver acetylome is a set of protein acetylation’s whose level reflects cellular metabolic health and is directly linked to intracellular pathways. However, to date, little is known about the cellular pathways that maintain the hepatic acetylome levels. Here, we show that macroautophagy hereafter referred to as autophagy, an intracellular lysosomal degradative pathway, regulates the hepatic acetylome.</p>